Douglas C. Harrington MD, BA

Dr. Douglas Harrington has over 25 years of experience in the research, development, commercialization, and expansion of innovative healthcare technology and services. Dr. Harrington was a member of one of the first heart transplant teams led by Dr. Jack Copeland from Stanford University. He cofounded one of the first clinical molecular biology laboratories in the U.S. with the NebraskaLymphoma Study Group headed by Dr. Jim Armitage. Dr. Harrington has developed multiple patents including detection of residual cancer cells, catalytic heavy metal extraction, and a patent pending for diagnosis and classification of cardiac disease. Dr. Harrington has taken over 200 academic discoveries into clinical use, founded a number of public and private biotechnology companies, and his PULS (Protein Unstable Lesion Signature) Cardiac Test was the recipient of the 2016 ABL Grand Prize Award for Innovation in Healthcare. Dr. Harrington is a Clinical Professor at the USC Keck School of Medicine, a published author of numerous peer-reviewed papers, and a sought after speaker in the area of preventive medicine and technology development. Dr. Harrington received his BA in molecular biolgoy, and M.D. from the University of Colorado Health Sciences Center, and is the CEO & Laboratory Director of Predictive Health Diagnostics